GlassScriptPhysician profile
Catherine Krenicky
NPI 1497988711
$4,735.41
in general payments reported to CMS, 2019-2025
36 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 88% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $637 · 2022: $860 · 2023: $1,167 · 2024: $1,002 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,229 · Education: $8.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,229.46 |
| Education | $8.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $862.36 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $597.72 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.54 | 2021-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $375.30 | 2023-2025 | Breztri, Farxiga |
| Amgen INC. | $309.14 | 2021-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $248.12 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $238.82 | 2021-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $194.17 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $166.52 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $145.88 | 2022-2024 | Eliquis |
| Sumitomo Pharma America, INC. | $144.79 | 2023-2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $110.80 | 2024-2025 | Voquezna |
| Abbvie INC. | $108.34 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.93 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $72.96 | 2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Krenicky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.